AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver
Not Applicable
Completed
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00272727
- Locations
- 🇩🇰
Research Site, Copenhagen, Denmark
Trial of Iressa in Prostate Cancer Patients
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00265070
- Locations
- 🇨🇦
Research Site, Montreal, Canada
Phase II Iressa & Carbo/Gem in NSCLC
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2009-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00264498
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 119
- Registration Number
- NCT00264004
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT00263965
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 389
- Registration Number
- NCT00263276
- Locations
- 🇵🇷
Local Institution, San Juan, Puerto Rico
🇨🇦Local institution, Bathurst, New Brunswick, Canada
🇺🇸Local Insitution, Edina, Minnesota, United States
C-Reactive Protein (CRP) in Obese Diabetic Women
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2007-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00262548
- Locations
- 🇲🇽
Research site, Cuernavaca, Morelos, Mexico
Dose Response Study in Japanese Patients
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00261417
- Locations
- 🇯🇵
Research Site, Takamori, Japan
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT00261287
- Locations
- 🇺🇸
Altana Pharma/Nycomed, San Antonio, Texas, United States
GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00261352
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
© Copyright 2024. All Rights Reserved by MedPath